

ENZO BIOCHEM

NO 6897
RECEIVED
CENTRAL FAX CENTER

JAN 21 2009

PTO/SB/08a (12-08)

Approved for use through 01/31/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/713,183
Filing Date	NOVEMBER 14, 2003
First Named Inventor	DEAN ENGELHARDT
Art Unit	1634
Examiner Name	KATHERINE SALMON
Attorney Docket Number	ENZ-52(D2)(C)(D1)

Sheet	1
-------	---

of 2

Attorney Docket Number	ENZ-52(D2)(C)(D1)
------------------------	-------------------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date	
Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 If possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

JAN. 21. 2009 1:45PM

ENZO BIOCHEM

RECEIVED
CENTRAL FAX CENTER 3

JAN 21 2009

PTO/SB/09b (12-08)

Approved for use through 01/31/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number

10/713,183

Filing Date

NOVEMBER 14, 2003

First Named Inventor

DEAN ENGELHARDT

Art Unit

1634

Examiner Name

KATHERINE SALMON

Attorney Docket Number

ENZ-52(D2)(C)(D1)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4	GAO ET AL., DIRECT IN VIVO GENE TRANSFER TO AIRWAY EPITHELIUM EMPLOYING ADENOVIRUS-POLYLYSINE-DNA COMPLEXES, HUMAN GENE THERAPY 4:17-24, 1993	
	5	WU ET AL., RECEPTOR-MEDIATED GENE DELIVERY, J. BIOL. CHEM., 263:14621-14624, 1988	
	6	CHEN ET AL., A SELF-INITIATING EUKARYOTIC TRANSIENT GENE EXPRESSION SYSTEM BASED ON COTRANSFECTION..., NUCLEIC ACIDS RES. 22:2114-2120, 1994	
	7	SHILATIFARD ET AL., THE NRA POLYMERASE II ELONGATION COMPLEX, ANN. REV. BIOCHEM., 72:693-715, 2003	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.